Taken together, these findings might add to the rationale of anti-VEGF therapy after completion of surgical and cytostatic first-line therapy of ovarian cancer, a concept currently under investigation in large phase III trials [42]. The gene discussed is VEGFA; the disease is ovarian cancer.